UCSF researchers have found that the majority of triple-negative breast cancers have a dysregulated MYC pathway, and the group has shown that CDK inhibitors such as Merck and Ligand's dinaciclib could selectively kill off these tumors. The group is planning a clinical trial to test an undisclosed CDK inhibitor in this patient population.